Filtering

DOP72: Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension studyECCO'20 Vienna
Year: 2020
Authors: Julián Panés
DOP72: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of Ulcerative Colitis: The open-label, multicentre, Phase 2a TUSCANY studyECCO'20 Vienna
Year: 2020
Authors: Silvio Danese
DOP73: Efficacy and safety of escalation to tofacitinib 10mg BID for patients with UC following loss of response on 5mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension studyECCO'20 Vienna
Year: 2020
Authors: Alessandro Armuzzi
DOP74: Ustekinumab is associated with better effectiveness outcomes when compared to vedolizumab in Crohn's Disease patients with prior anti-TNF failure: Comparative effectiveness study from the ICC RegistryECCO'20 Vienna
Year: 2020
Authors: Marieke Pierik
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extensionECCO'20 Vienna
Year: 2020
Authors: Laurent Peyrin-Biroulet
DOP78: Intestinal surgery rates in Ulcerative Colitis and Crohn’s Disease in the era of biologics – A Danish Nationwide Register Study from 2003-2016ECCO'20 Vienna
Year: 2020
Authors: Niels Qvist
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST studyECCO'20 Vienna
Year: 2020
Authors: William Sandborn
DOP80: Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s Disease refractory to anti-tumor necrosis factor: A multi-center comparative studyECCO'20 Vienna
Year: 2020
Authors: Hadrien Alric
DOP81: Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE SustainECCO'20 Vienna
Year: 2020
Authors: Séverine Vermeire
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectinECCO'20 Vienna
Year: 2020
Authors: Marte Becker
DOP84: Crohn’s Disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remissionECCO'20 Vienna
Year: 2020
Authors: Carolina Serena
DOP87: SUCNR1 a novel key protagonist in fistula developmentECCO'20 Vienna
Year: 2020
Authors: Jesús Cosín-Roger
DOP88: Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s Disease patientsECCO'20 Vienna
Year: 2020
Authors: Zixiang Lim
Drugs of the future: Update on developmental agentsECCO'20 Vienna
Year: 2020
Authors: William Sandborn
Dysplasia – discussion (Tandem talk)5th H-ECCO IBD Masterclass
Year: 2020
Authors: Francesca Rosini, Gert de Hertogh
Early Crohn’s: Surgery first and early medicine later? (Tandem Talk)ECCO'20 Vienna
Year: 2020
Authors: Alessandro Armuzzi, André Jan Louis D'Hoore
ECCO ESPGHAN Guideline Pitch on Paediatric CD (update)ECCO'20 Vienna
Year: 2020
Authors: Patrick Van Rheenen
ECCO Lecture: How organoids model human diseaseECCO'20 Vienna
Year: 2020
Authors: Hans Clevers
ECCO Quality Standards of CareECCO'20 Vienna
Year: 2020
Authors: Gionata Fiorino
Examples of atypia - slide seminar (Tandem talk)5th H-ECCO IBD Masterclass
Year: 2020
Authors: Francesca Rosini, Gert de Hertogh